Milan - Delayed Quote EUR

REGENERON PHARMACEUTICALS (1REGN.MI)

Compare
687.00
-29.00
(-4.05%)
At close: January 2 at 10:13:08 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 1REGN.MI

Recent News: 1REGN.MI

View More
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
GlobeNewswire 4 days ago
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years
Simply Wall St. 11 days ago
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
GlobeNewswire 23 days ago
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 25 days ago
Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial

Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
The Wall Street Journal 25 days ago
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
GlobeNewswire 25 days ago
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
GlobeNewswire 26 days ago
Regeneron reinstated with an Underperform at BofA

Regeneron reinstated with an Underperform at BofA
TipRanks last month
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
GlobeNewswire last month
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
GlobeNewswire last month
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Simply Wall St. last month
View More

Related Tickers

0K4.F Akero Therapeutics, Inc.
25.36
+0.71%
 
0MGB.IL Genmab A/S
1,601.75
+0.28%
 
1VT.BE Viking Therapeutics Inc
38.60
-3.67%
 
ORKA Oruka Therapeutics, Inc.
15.72
-17.31%
 
LIPO Lipella Pharmaceuticals Inc.
2.9000
-8.52%
 
HRMY Harmony Biosciences Holdings, Inc.
33.86
-1.94%
 
URGN UroGen Pharma Ltd.
10.24
-7.25%
 
PCVX Vaxcyte, Inc.
81.08
+0.02%
 
MRUS Merus N.V.
43.85
+3.84%
 
KOD Kodiak Sciences Inc.
8.32
-9.57%